Moderna
Norwood, MA
ARCHITECT
DPS, TRIA
TYPE
cGMP, Lab, Office
SF
200,000
INDUSTRY
Biopharmaceutical
CM
Wise Construction
Awards & Recognition
2019 ISPE Facility of the Future
LEED Gold Certified
Owner’s Representative for a state-of-the-art facility.
Hereva was hired as Owner’s Representative to manage the programming, engineering, design and construction of this 200,000 sq. ft. state-of-the-art drug substance processing and cGMP manufacturing facility. The site in Norwood, MA provided collaboration and amenity spaces for staff, as well as open offices for over 200 people. The facility won ISPE’s prestigious Facility of the Future Award.
Project completed in 2018.
About the project
Moderna Therapeutics, founded in 2011, has experienced unprecedented growth in the clinical development of mRNA therapies for numerous diseases and vaccinations. In 2016, the company decided to embark upon its first cGMP manufacturing facility and selected Norwood, MA to be its site. Hereva was consulted during the site selection process and was retained by Moderna as Owner’s Representative to manage the programming, engineering and design of this drug substance processing and cGMP manufacturing facility.
Formerly a Polaroid plant, the 200,000 sq. ft. facility in Norwood houses all clinical manufacturing activities, from raw material production to active pharmaceutical ingredients (APIs), formulation, filling and finish. In addition to the cGMP manufacturing and warehouse areas, the building houses all associated quality and building infrastructure services, approximately 25,000 sq. ft. of collaborative, open plan office and an amenities hub that contains a cafeteria, fitness center, training and conference facilities, and numerous employee recreation and meeting areas.
Hereva worked closely with Moderna to develop a facility that is state-of-the-art and modern in its design, and carefully tied to the community remaining in Cambridge. Key features of the design reflect Moderna’s branding and corporate identity, and high-tech AV systems connect the site to other Moderna sites in Cambridge and beyond.
The facility was officially opened on July 17, 2018. The project value exceeds $100M and was designed to achieve LEED Gold Certification.
About the client
Moderna is pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching. It could transform not only how certain diseases are treated but also how medicines are discovered, developed and manufactured – at a breadth, scale and speed not common in the biopharma industry.
Since foundation in 2011, they have built the industry’s leading mRNA technology platform, the infrastructure to accelerate drug discovery and speed early development, a rapidly expanding pipeline, and an unparalleled team.
For more information visit www.modernatx.com.